Cargando…
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion of NSCLC depends on oncogenic molecular aberratio...
Autor principal: | Rothschild, Sacha I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491691/ https://www.ncbi.nlm.nih.gov/pubmed/26018876 http://dx.doi.org/10.3390/cancers7020816 |
Ejemplares similares
-
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016) -
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015) -
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015) -
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
por: König, David, et al.
Publicado: (2021) -
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)